(GEHC) GE HealthCare Technologies - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 29.263m USD | Total Return: -7% in 12m
Avg Turnover: 340M
EPS Trend: 76.9%
Qual. Beats: 0
Rev. Trend: 82.8%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
GE HealthCare Technologies Inc. (GEHC) is a global medical technology company specializing in diagnostic imaging, patient monitoring, and pharmaceutical diagnostics. The company operates through four primary segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Its portfolio encompasses a wide range of hardware and digital solutions, including MRI and CT scanners, ultrasound systems, patient monitoring devices, and contrast media used in nuclear medicine.
The medical technology sector is characterized by high barriers to entry due to significant research and development costs and rigorous regulatory approval processes. GEHC follows a diversified business model that combines capital equipment sales with recurring revenue streams from consumables, maintenance services, and integrated digital software solutions. Investors can evaluate the company’s long-term valuation metrics by visiting ValueRay.
- Aging global population increases demand for high-end diagnostic imaging and molecular tracers
- Expansion of precision medicine and AI-integrated digital solutions improves long-term profit margins
- Strategic contrast media supply chain investments mitigate pharmaceutical diagnostic segment supply risks
- Hospital capital expenditure cycles and reimbursement rate changes impact medical equipment order volume
| Net Income: 1.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.00 > 1.0 |
| NWC/Revenue: 7.28% < 20% (prev -3.00%; Δ 10.27% < -1%) |
| CFO/TA 0.05 > 3% & CFO 2.03b > Net Income 1.50b |
| Net Debt (8.73b) to EBITDA (3.08b): 2.84 < 3 |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (457.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 42.55% > 18% (prev 0.42%; Δ 4.21k% > 0.5%) |
| Asset Turnover: 56.44% > 50% (prev 58.95%; Δ -2.51% > 0%) |
| Interest Coverage Ratio: 5.71 > 6 (EBITDA TTM 3.08b / Interest Expense TTM 435.0m) |
| A: 0.04 (Total Current Assets 9.98b - Total Current Liabilities 8.53b) / Total Assets 37.1b |
| B: 0.15 (Retained Earnings 5.65b / Total Assets 37.1b) |
| C: 0.07 (EBIT TTM 2.49b / Avg Total Assets 35.4b) |
| D: 0.16 (Book Value of Equity 4.26b / Total Liabilities 26.2b) |
| Altman-Z'' = 1.40 = BB |
| DSRI: 1.08 (Receivables 4.74b/4.35b, Revenue 20.0b/19.8b) |
| GMI: 0.99 (GM 42.55% / 41.99%) |
| AQI: 1.02 (AQ_t 0.65 / AQ_t-1 0.64) |
| SGI: 1.01 (Revenue 20.0b / 19.8b) |
| TATA: -0.01 (NI 1.50b - CFO 2.03b) / TA 37.1b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 64.33 with a total of 5,016,566 shares traded.
Over the past week, the price has changed by +5.71%,
over one month by -8.10%,
over three months by -23.37% and
over the past year by -6.96%.
GE HealthCare Technologies has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy GEHC.
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 80 | 24.3% |
P/E Forward = 13.1752
P/S = 1.3949
P/B = 2.7431
P/EG = 1.8183
Revenue TTM = 20.0b USD
EBIT TTM = 2.49b USD
EBITDA TTM = 3.08b USD
Long Term Debt = 10.1b USD (from longTermDebt, last quarter)
Short Term Debt = 139.0m USD (from shortTermDebt, last quarter)
Debt = 11.0b USD (from shortLongTermDebtTotal, last quarter) + Leases 443.0m
Net Debt = 8.73b USD (calculated: Debt 11.0b - CCE 2.29b)
Enterprise Value = 38.0b USD (29.3b + Debt 11.0b - CCE 2.29b)
Interest Coverage Ratio = 5.71 (Ebit TTM 2.49b / Interest Expense TTM 435.0m)
EV/FCF = 25.00x (Enterprise Value 38.0b / FCF TTM 1.52b)
FCF Yield = 4.00% (FCF TTM 1.52b / Enterprise Value 38.0b)
FCF Margin = 7.62% (FCF TTM 1.52b / Revenue TTM 20.0b)
Net Margin = 7.54% (Net Income TTM 1.50b / Revenue TTM 20.0b)
Gross Margin = 42.55% ((Revenue TTM 20.0b - Cost of Revenue TTM 11.5b) / Revenue TTM)
Gross Margin QoQ = 38.53% (prev 54.34%)
Tobins Q-Ratio = 1.02 (Enterprise Value 38.0b / Total Assets 37.1b)
Interest Expense / Debt = 3.95% (Interest Expense 435.0m / Debt 11.0b)
Taxrate = 18.61% (94.0m / 505.0m)
NOPAT = 2.02b (EBIT 2.49b * (1 - 18.61%))
Current Ratio = 1.17 (Total Current Assets 9.98b / Total Current Liabilities 8.53b)
Debt / Equity = 1.03 (Debt 11.0b / totalStockholderEquity, last quarter 10.7b)
Debt / EBITDA = 2.84 (Net Debt 8.73b / EBITDA 3.08b)
Debt / FCF = 5.75 (Net Debt 8.73b / FCF TTM 1.52b)
Total Stockholder Equity = 10.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.26% (Net Income 1.50b / Total Assets 37.1b)
RoE = 14.77% (Net Income TTM 1.50b / Total Stockholder Equity 10.2b)
RoCE = 12.24% (EBIT 2.49b / Capital Employed (Equity 10.2b + L.T.Debt 10.1b))
RoIC = 7.09% (NOPAT 2.02b / Invested Capital 28.6b)
WACC = 8.50% (E(29.3b)/V(40.3b) * Re(10.49%) + D(11.0b)/V(40.3b) * Rd(3.95%) * (1-Tc(0.19)))
Discount Rate = 10.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -18.16 | Cagr: -0.10%
[DCF] Terminal Value 76.23% ; FCFF base≈1.46b ; Y1≈1.60b ; Y5≈2.00b
[DCF] Fair Price = 46.38 (EV 29.8b - Net Debt 8.73b = Equity 21.1b / Shares 454.9m; r=8.50% [WACC]; 5y FCF grow 10.63% → 2.50% )
EPS Correlation: 76.93 | EPS CAGR: 6.50% | SUE: -0.48 | # QB: 0
Revenue Correlation: 82.77 | Revenue CAGR: 1.51% | SUE: 1.19 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.04 | Chg30d=-10.91% | Revisions=-68% | Analysts=15
EPS next Quarter (2026-09-30): EPS=1.25 | Chg30d=-0.94% | Revisions=-6% | Analysts=15
EPS current Year (2026-12-31): EPS=4.88 | Chg30d=-3.44% | Revisions=-73% | GrowthEPS=+6.4% | GrowthRev=+5.6%
EPS next Year (2027-12-31): EPS=5.37 | Chg30d=-3.37% | Revisions=-64% | GrowthEPS=+10.0% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -73%